RXi Pharmaceuticals (NASDAQ:RXII) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.04, MarketWatch Earnings reports. The company had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.05 million.

Shares of NASDAQ RXII traded down $0.01 on Thursday, hitting $0.33. The company’s stock had a trading volume of 26,355 shares, compared to its average volume of 599,172. RXi Pharmaceuticals has a 12-month low of $0.31 and a 12-month high of $7.70. The company has a market capitalization of $1.53 million, a PE ratio of -0.08 and a beta of 2.07.

A number of analysts recently commented on RXII shares. HC Wainwright reissued a “buy” rating on shares of RXi Pharmaceuticals in a report on Monday, October 15th. ValuEngine raised shares of RXi Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd.

A hedge fund recently bought a new stake in RXi Pharmaceuticals stock. SG Americas Securities LLC purchased a new stake in RXi Pharmaceuticals Corp (NASDAQ:RXII) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 118,387 shares of the biotechnology company’s stock, valued at approximately $228,000. SG Americas Securities LLC owned approximately 2.78% of RXi Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.91% of the company’s stock.

TRADEMARK VIOLATION WARNING: “RXi Pharmaceuticals (RXII) Issues Earnings Results, Beats Expectations By $0.04 EPS” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/11/15/rxi-pharmaceuticals-rxii-issues-earnings-results-beats-expectations-by-0-04-eps.html.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

Further Reading: How does a reverse stock split work?

Earnings History for RXi Pharmaceuticals (NASDAQ:RXII)

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.